BOLT Bolt Biotherapeutics, Inc. - Common Stock
$3,22
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 11, 2026
Zakres 52 tyg.
$3–$7
2% of range
Ocena Analityków
BUY
10 analysts
Cena Docelowa
$29
+801% upside
P/E (TTM)
-0.2
ROE
-102.2%
Marża Zysku Netto
-433.7%
BOLT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$3.22
Kapitalizacja Rynkowa
$6M
P/E (TTM)
-0.2
EPS (TTM)
$-17.85
Przychody (TTM)
$8M
Stopa dywidendy
—
ROE
-102.2%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$3 – $7
BOLT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$8M
2020-12-31
→
2025-12-31
EPS
$-17.85
2021-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-40M
2021-12-31
→
2025-12-31
Marże
-433.7%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
BOLT
Mediana porównawcza
P/E (TTM)
-0.2
—
P/S (TTM)
0.8
2.9
P/B
0.2
1.1
Price / FCF (Cena / FCF)
-0.2
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
BOLT
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-469.3%
—
Net Profit Margin (Marża Zysku Netto)
-433.7%
-4409.1%
ROA
-42.7%
-111.4%
ROE
-102.2%
-169.4%
ROIC
-136.2%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
BOLT
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
3.6
1.9
Quick Ratio (Wskaźnik Szybkości)
3.3
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
BOLT
Mediana porównawcza
Revenue YoY (Przychody R/R)
0.07%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
10.3%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
101.6%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
BOLT
Mediana porównawcza
BOLT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
10 analityków
- Mocne kupno 2 20,0%
- Kup 5 50,0%
- Trzymaj 3 30,0%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
3 analityków · 2026-08-17
Mediana
$7.00
Średnia
$29.00
← Poniżej wszystkich celów
$3.22
Niski
$5.00
Wysoki
$75.00
Średni cel
$7.00
+117,4%
Średnia cel
$29.00
+800,6%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
1.2%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 31 marca 2026 | $-4.31 | $-2.91 | -1.4% |
| 31 grudnia 2025 | $-3.84 | $-6.23 | 2.4% |
| 30 września 2025 | $-3.72 | $-5.90 | 2.2% |
| 30 czerwca 2025 | $-4.46 | $-6.58 | 2.1% |
| 31 marca 2025 | $-5.80 | $-7.39 | 1.6% |
| 31 grudnia 2024 | $-7.60 | $-7.75 | 0.15% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| BOLT | $11M | -0.3 | 0.07% | -433.7% | -102.2% | — |
| ALZN | $5M | -0.4 | — | — | -598.1% | — |
| FBLG | — | -0.5 | — | — | — | — |
| ERNA | — | — | — | — | — | — |
| ENSC | $4M | -0.2 | -2.8% | -200.9% | -294.0% | — |
| CDIO | — | — | — | — | — | — |
| ACXP | $6M | -0.5 | — | — | -180.3% | — |
| PMCB | $8M | -0.3 | — | — | -56.7% | — |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| XBIO | — | -1.4 | 19.0% | — | — | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| R&D Expense | $29M | $57M | $62M | $73M | $76M | $40M | |
| SG&A Expense | $14M | $18M | $23M | $23M | $18M | $9M | |
| Operating Expenses | $44M | $81M | $84M | $96M | $94M | $49M | |
| Operating Income | $-36M | $-73M | $-76M | $-90M | $-93M | $-49M | |
| Other Non-op | $3M | $10M | $7M | $2M | $-6M | $-12M | |
| Pretax Income | $-33M | $-63M | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| EPS (Basic) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| EPS (Diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| Shares (Basic) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | 1,989,208 | |
| Shares (Diluted) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | · | |
| EBITDA | $-35M | $-71M | $-74M | $-89M | $-92M | · |
Bilans 20
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12M | $7M | $11M | $9M | $27M | $6M | |
| Short-term Investments | $16M | $40M | $91M | $160M | $159M | $17M | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $3M | $3M | |
| Current Assets | $30M | $51M | $106M | $173M | $189M | $25M | |
| PP&E (Net) | $1M | $3M | $5M | $6M | $6M | $4M | |
| PP&E (Gross) | $9M | $10M | $11M | $10M | $8M | $5M | |
| Accum. Depreciation | $7M | $7M | $6M | $4M | $2M | $1M | |
| Other Non-current Assets | $138.0K | $62.0K | $2M | $1M | $1M | $909.0K | |
| Total Assets | $57M | $100M | $160M | $228M | $308M | $47M | |
| Accounts Payable | $1M | $2M | $3M | $4M | $4M | $2M | |
| Current Liabilities | $8M | $16M | $20M | $23M | $21M | $11M | |
| Capital Leases | $20M | $23M | $17M | $20M | $22M | $9M | |
| Other Non-current Liabilities | $132.0K | $0 | $43.0K | $42.0K | $210.0K | $329.0K | |
| Total Liabilities | $30M | $42M | $47M | $56M | $58M | $46M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | · | |
| Retained Earnings | $-461M | $-427M | $-364M | $-295M | $-207M | $-108M | |
| AOCI | $-21.0K | $97.0K | $37.0K | $-919.0K | $-321.0K | · | |
| Stockholders' Equity | $27M | $57M | $113M | $172M | $250M | $-105M | |
| Liabilities + Equity | $57M | $100M | $160M | $228M | $308M | $47M | |
| Shares Outstanding | 1,920,566 | 1,916,943 | 38,114,606 | 37,797,902 | 37,399,694 | 2,130,139 |
Przepływy pieniężne 12
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $1M | $611.0K | |
| Stock-based Comp | $3M | $7M | $9M | $10M | $8M | $1M | |
| Restructuring | $1M | $3M | $0 | · | · | · | |
| Other Non-cash | $-11M | $-7M | $-11M | $352.0K | $32M | · | |
| Operating Cash Flow | $-40M | $-61M | $-70M | $-77M | $-57M | $-47M | |
| CapEx | $72.0K | $41.0K | $206.0K | $2M | $2M | $3M | |
| Investing Cash Flow | $44M | $58M | $71M | $58M | $-232M | $-21M | |
| Stock Issued | $19.0K | $108.0K | $253.0K | $503.0K | $1M | $294.0K | |
| Net Stock Activity | $19.0K | $108.0K | $253.0K | $503.0K | $1M | · | |
| Financing Cash Flow | $19.0K | $108.0K | $253.0K | $503.0K | $311M | $40M | |
| Net Change in Cash | $4M | $-4M | $2M | $-18M | $22M | $-28M | |
| Free Cash Flow | $-40M | $-61M | $-70M | $-78M | $-59M | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% | · | |
| Net Margin | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% | · | |
| Pretax Margin | -433.7% | · | · | · | · | · | |
| EBITDA Margin | -452.5% | -926.8% | -943.9% | -1547.5% | -7269.4% | · | |
| ROA | -42.7% | -48.7% | -35.7% | -32.9% | -55.7% | · | |
| ROE | -102.2% | -97.7% | -57.4% | -48.9% | -37.6% | · | |
| ROIC | -136.2% | · | · | · | · | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 | · | |
| Quick Ratio | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 | · |
Efektywność 1
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.07% | -2.4% | 37.5% | 354.7% | 445.5% | · | |
| Revenue CAGR 3Y | 10.3% | 82.8% | 224.3% | · | · | · | |
| Revenue CAGR 5Y | 101.6% | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| Net Income TTM | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| Market Cap | $11M | $410M | $854M | $983M | $3.67B | · | |
| P/E | -0.3 | -0.3 | -12.2 | -11.0 | -33.0 | · | |
| P/S | 1.4 | 53.3 | 108.4 | 171.5 | 2908.9 | · | |
| P/B | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Tangible Book | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Cash Flow | -0.3 | -6.7 | -12.3 | -12.8 | -64.2 | · | |
| P / FCF | -0.3 | -6.7 | -12.2 | -12.5 | -61.7 | · | |
| Earnings Yield | -326.4% | -309.0% | -8.2% | -9.1% | -3.0% | · |
Rachunek zysków i strat 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $26.0K | $2M | $2M | $2M | $1M | $0 | $1M | $1M | $5M | $2M | $3M | $1M | $2M | $1M | $2M | |
| R&D Expense | $5M | $5M | $5M | $7M | $7M | $10M | $12M | $14M | $15M | $17M | $16M | $15M | $16M | $15M | $17M | $19M | |
| SG&A Expense | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | |
| Operating Expenses | $8M | $8M | $10M | $10M | $11M | $13M | $17M | $18M | $24M | $22M | $22M | $21M | $21M | $20M | $22M | $24M | |
| Operating Income | $-8M | $-8M | $-7M | $-8M | $-9M | $-12M | $-17M | $-16M | $-23M | $-17M | $-20M | $-18M | $-20M | $-18M | $-21M | $-22M | |
| Other Non-op | $654.0K | $357.0K | $454.0K | $559.0K | $649.0K | $1M | $980.0K | $1M | $1M | $6M | $2M | $2M | $2M | $1M | $1M | $587.0K | |
| Net Income | $-8M | $-7M | $-7M | $-7M | $-9M | $-11M | $-16M | $-15M | $-21M | $-11M | $-18M | $-16M | $-18M | $-17M | $-20M | $-22M | |
| EPS (Basic) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| EPS (Diluted) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| Shares (Basic) | 1,690,529 | 1,680,445 | -40,306,843 | 1,919,441 | 1,917,629 | 1,916,943 | -39,978,249 | 1,912,554 | 1,906,496 | 38,068,424 | -75,490,912 | 37,868,480 | 37,750,393 | 37,684,023 | -74,517,348 | 37,454,340 | |
| Shares (Diluted) | 1,690,529 | 1,680,445 | -40,306,843 | 1,919,441 | 1,917,629 | 1,916,943 | -39,978,249 | 1,912,554 | 1,906,496 | 38,068,424 | -75,490,912 | 37,868,480 | 37,750,393 | 37,684,023 | -74,517,348 | 37,454,340 | |
| EBITDA | $-8M | $-7M | · | $-8M | $-9M | $-12M | · | $-16M | $-23M | $-17M | · | $-18M | $-20M | $-18M | · | $-22M |
Bilans 20
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13M | $12M | $12M | $18M | $10M | $8M | $7M | $9M | $6M | $4M | $11M | $9M | $13M | $15M | $9M | $11M | |
| Short-term Investments | $5M | $11M | $16M | $14M | $25M | $30M | $40M | $44M | $67M | $87M | $91M | $111M | $112M | $112M | $160M | $161M | |
| Prepaid Expense | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $6M | $5M | $5M | $4M | $4M | |
| Current Assets | $21M | $26M | $30M | $36M | $38M | $43M | $51M | $57M | $77M | $95M | $106M | $125M | $131M | $132M | $173M | $175M | |
| PP&E (Net) | $571.0K | $1M | $1M | $2M | $2M | $2M | $3M | $4M | $4M | $4M | $5M | $5M | $6M | $6M | $6M | $7M | |
| PP&E (Gross) | $4M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $4M | $8M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | |
| Other Non-current Assets | $87.0K | $112.0K | $138.0K | $179.0K | $222.0K | $51.0K | $62.0K | $287.0K | $308.0K | $2M | $2M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Accounts Payable | $868.0K | $2M | $1M | $2M | $2M | $2M | $2M | $1M | $3M | $2M | $3M | $4M | $3M | $2M | $4M | $4M | |
| Current Liabilities | $8M | $7M | $8M | $10M | $12M | $14M | $16M | $18M | $18M | $17M | $20M | $19M | $18M | $16M | $23M | $24M | |
| Capital Leases | $19M | $19M | $20M | $21M | $22M | $22M | $23M | $15M | $16M | $17M | $17M | $18M | $19M | $20M | $20M | $21M | |
| Other Non-current Liabilities | $132.0K | $158.0K | $132.0K | $133.0K | $133.0K | $132.0K | $0 | $0 | $0 | $0 | $43.0K | $43.0K | $43.0K | $43.0K | $42.0K | $200.0K | |
| Total Liabilities | $28M | $28M | $30M | $33M | $37M | $39M | $42M | $37M | $38M | $39M | $47M | $47M | $49M | $48M | $56M | $57M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0K | $1.0K | $1.0K | $0 | $1.0K | $1.0K | $0 | $0 | $0 | |
| Retained Earnings | $-476M | $-468M | $-461M | $-454M | $-447M | $-438M | $-427M | $-411M | $-396M | $-375M | $-364M | $-346M | $-330M | $-312M | $-295M | $-275M | |
| AOCI | $-44.0K | $-11.0K | $-21.0K | $-10.0K | $-6.0K | $40.0K | $97.0K | $205.0K | $-44.0K | $-36.0K | $37.0K | $-174.0K | $-229.0K | $-235.0K | $-919.0K | $-2M | |
| Stockholders' Equity | $13M | $20M | $27M | $32M | $39M | $47M | $57M | $72M | $86M | $104M | $113M | $128M | $142M | $158M | $172M | $188M | |
| Liabilities + Equity | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Shares Outstanding | 1,926,345 | 1,921,567 | 1,920,566 | 1,919,441 | 1,919,441 | 38,339,697 | 1,916,943 | 38,273,002 | 38,264,843 | 38,127,740 | 38,114,606 | 37,965,870 | 37,950,986 | 37,813,037 | 37,797,902 | 37,660,893 |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $171.0K | $203.0K | $255.0K | $290.0K | $347.0K | $399.0K | $426.0K | $440.0K | $457.0K | $458.0K | $467.0K | $462.0K | $458.0K | $467.0K | $462.0K | $439.0K | |
| Stock-based Comp | $552.0K | $545.0K | $1M | $407.0K | $625.0K | $709.0K | $1M | $1M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | $1M | $0 | $0 | · | $-222.0K | $0 | $4M | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-2M | · | · | · | $-3M | · | · | · | $-9M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $-7M | $-8M | $-7M | $-10M | $-10M | $-13M | $-14M | $-14M | $-16M | $-17M | $-14M | $-17M | $-15M | $-23M | $-18M | $-13M | |
| CapEx | · | · | $0 | $72.0K | · | · | $0 | $41.0K | $0 | $0 | $6.0K | $165.0K | $32.0K | $3.0K | $184.0K | $735.0K | |
| Investing Cash Flow | $8M | $8M | $1M | $18M | $11M | $15M | $12M | $17M | $18M | $10M | $16M | $13M | $14M | $29M | $16M | $1M | |
| Stock Issued | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | · | · | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Stock Activity | · | $6.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | $79.0K | $0 | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Change in Cash | $1M | $-94.0K | $-6M | $8M | $1M | $1M | $-2M | $3M | $2M | $-7M | $2M | $-4M | $-1M | $6M | $-1M | $-12M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-17M | · | · | · | $-23M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -167480.0% | -29234.6% | · | -355.1% | -510.5% | -991.4% | · | -1441.1% | -1772.3% | -324.1% | · | -719.3% | -1383.9% | -1008.5% | · | -1058.1% | |
| Net Margin | -154400.0% | -27861.5% | · | -329.4% | -474.6% | -903.4% | · | -1330.1% | -1662.3% | -205.0% | · | -643.1% | -1260.1% | -929.9% | · | -1030.3% | |
| EBITDA Margin | -167480.0% | -28453.8% | · | -355.1% | -510.5% | -958.8% | · | -1441.1% | -1772.3% | -315.4% | · | -719.3% | -1383.9% | -982.9% | · | -1058.1% | |
| ROA | -13.3% | -10.8% | · | -8.2% | -8.6% | -9.7% | · | -10.7% | -13.5% | -6.2% | · | -7.7% | -8.0% | -7.0% | · | -7.5% | |
| ROE | -30.0% | -21.7% | · | -13.7% | -13.7% | -14.6% | · | -15.2% | -18.6% | -8.3% | · | -10.3% | -10.3% | -8.8% | · | -9.4% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | 3.5 | · | 3.6 | 3.1 | 3.1 | · | 3.2 | 4.3 | 5.7 | · | 6.7 | 7.4 | 8.1 | · | 7.2 | |
| Quick Ratio | 2.2 | 3.1 | · | 3.2 | 2.8 | 2.9 | · | 3.0 | 4.1 | 5.5 | · | 6.4 | 7.1 | 7.8 | · | 7.1 |
Efektywność 1
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $5M | · | $6M | $5M | $9M | · | $10M | $11M | $11M | · | $8M | $7M | $6M | · | $5M | |
| Net Income TTM | $-31M | $-34M | · | $-42M | $-56M | $-58M | · | $-63M | $-66M | $-62M | · | $-73M | $-79M | $-85M | · | $-91M | |
| Market Cap | $7M | $8M | · | $10M | $11M | $307M | · | $496M | $574M | $1.07B | · | $790M | $972M | $1.05B | · | $1.11B | |
| P/E | -0.2 | -0.2 | · | -0.3 | -0.2 | -0.4 | · | -0.7 | -1.2 | -17.1 | · | -10.7 | -12.1 | -12.2 | · | -12.0 | |
| P/S | 1.9 | 1.5 | · | 1.6 | 2.0 | 34.4 | · | 48.5 | 54.6 | 96.5 | · | 100.0 | 143.6 | 171.1 | · | 219.9 | |
| P/B | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | 5.9 | |
| P / Tangible Book | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | 5.9 | |
| P / Cash Flow | · | -1.0 | · | · | · | -22.9 | · | · | · | -63.7 | · | · | · | -44.9 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -63.7 | · | · | · | -44.9 | · | · | |
| Earnings Yield | -443.1% | -451.7% | · | -308.3% | -412.5% | -245.2% | · | -152.5% | -82.1% | -5.9% | · | -9.3% | -8.3% | -8.2% | · | -8.3% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $8M | $8M | $8M | $6M | $1M |
| Marża Operacyjna % | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% |
| Zysk netto | $-33M | $-63M | $-69M | $-88M | $-99M |
| Rozwodniony EPS | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 |
| Wskaźnik Szybkości | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-40M | $-61M | $-70M | $-78M | $-59M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 25 emitentów · $2.3M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 5 (+2 vs poprzedni kw.) | 2 (0 vs poprzedni kw.) | 5 (+1 vs poprzedni kw.) | 2 (-1 vs poprzedni kw.) | -6K |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | $530 226 | 137 721 | 23,51% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $379 706 | 98 625 | 16,83% | Akcje |
| Vivo Capital, LLC | $278 794 | 72 414 | 12,36% | Akcje |
| CITADEL ADVISORS LLC | $219 077 | 56 903 | 9,71% | Akcje |
| T3 Companies, LLC | $146 300 | 38 000 | 6,49% | Akcje |
| Board of Trustees of The Leland Stanford Junior University | $138 511 | 35 977 | 6,14% | Akcje |
| Pfizer Inc | $133 832 | 31 305 | 5,93% | Akcje |
| Lynx1 Capital Management LP | $118 580 | 30 800 | 5,26% | Akcje |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $105 875 | 27 500 | 4,69% | Akcje |
| Shay Capital LLC | $59 436 | 15 438 | 2,64% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $56 078 | 14 562 | 2,49% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $27 181 | 7 060 | 1,21% | Akcje |
| Nan Fung Group Holdings Ltd | $19 250 | 5 000 | 0,85% | Akcje |
| MORGAN STANLEY | $12 043 | 3 128 | 0,53% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $11 916 | 3 095 | 0,53% | Akcje |
| NewEdge Advisors, LLC | $9 740 | 2 530 | 0,43% | Akcje |
| Tower Research Capital LLC (TRC) | $6 584 | 1 710 | 0,29% | Akcje |
| MERCER GLOBAL ADVISORS INC /ADV | $1 124 | 292 | 0,05% | Akcje |
| SBI Securities Co., Ltd. | $501 | 130 | 0,02% | Akcje |
| BlackRock, Inc. | $343 | 89 | 0,02% | Akcje |
| JPMORGAN CHASE & CO | $165 | 42 | 0,01% | Akcje |
| CITIGROUP INC | $158 | 41 | 0,01% | Akcje |
| VANGUARD GROUP INC | $132 | 24 | 0,01% | Akcje |
| BARCLAYS PLC | $23 | 6 | 0,00% | Akcje |
| UBS Group AG | $8 | 2 | 0,00% | Akcje |
Insiderzy spółki 18 insiderów · 6 dyrektorzy generalni · 13 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William P. Quinn | President, CEO and CFO | 28 stycznia 2026 A | 2 313 | 2 | 0 | $1 262 |
| Randall C Schatzman | Chief Executive Officer | 4 marca 2024 A | 1 500 | 0 | 0 | $0 |
| Grant Yonehiro | Chief Operating Officer | 28 stycznia 2026 A | 38 918 | 0 | 0 | $0 |
| Sarah Nemec | Senior VP, Finance and PAO | 28 stycznia 2026 A | 1 415 | 2 | 0 | $1 262 |
| Edith A. Perez | Chief Medical Officer | 4 marca 2024 A | 37 042 | 0 | 0 | $0 |
| David Dornan | Chief Scientific Officer | 18 lutego 2022 A | — | 0 | 0 | $0 |
| Laura Berner | Dyrektor | 10 czerwca 2026 A | — | 0 | 0 | $0 |
| Jakob Dupont | Dyrektor | 10 czerwca 2026 A | — | 0 | 0 | $0 |
| Brian O'Callaghan | Dyrektor | 10 czerwca 2026 A | — | 0 | 0 | $0 |
| Nicole Onetto | Dyrektor | 10 czerwca 2026 A | — | 0 | 0 | $0 |
| Kathleen Laporte | Dyrektor | 10 czerwca 2026 A | 1 200 | 0 | 0 | $0 |
| Frank D. Lee | Dyrektor | 12 czerwca 2024 A | — | 0 | 0 | $0 |
| Mahendra Shah | Dyrektor | 12 czerwca 2024 A | 1 448 286 | 0 | 0 | $0 |
| Dr. James I. Healy | Dyrektor | 12 czerwca 2024 A | 2 754 437 | 0 | 0 | $0 |
| Edgar Engleman | Dyrektor | 30 listopada 2023 S | 251 522 | 0 | 0 | $0 |
| Richard A Miller MD | Dyrektor | 12 czerwca 2023 A | — | 0 | 0 | $0 |
| Ashish Siri Ram Khanna | Dyrektor | 9 lutego 2021 P | 1 200 | 0 | 0 | $0 |
| Novo Holdings A/S | Posiadacz 10% | 13 lipca 2022 S | 3 703 991 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited, Permwell Management Limited, NFLS Beta Limited, NFLS Platform Holdings Limited ×4 zgłoszenia | 26 lutego 2026 | 4,60% | Aneks | — | SEC |
| Novo Holdings A/S ×6 zgłoszenia | 4 stycznia 2023 | — | Pierwotne zgłoszenie | — | SEC |
| Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P., Ltd. | 17 lutego 2021 | — | Pierwotne zgłoszenie | — | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.L.C. (“SM X”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) | 16 lutego 2021 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 1 fundusz ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 7 060 SH | 8 sierpnia 2026 | Dziennie |